BRIEF-Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.